Polymyositis anti-SRP antibodies and pregnancy about 2 cases

Cissé, Ousmane; Makhtar, Ba El Hadji; Fatoumata, Ba; Massi, Gams Daniel; Lémine, Daddah Sami Mouhamed; Soda, Diop-Sène Marieme; Dieynaba, Sow Adjaratou; Anna, Basse; Bouna, Seck Lala; Ndiaye, M.; Gallo, Diop Amadou; Mansour, Ndiaye Mouhamadou

doi:10.11604/pamj.2016.24.192.9690

Cited by 6 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They speculated that overexposure to fetal TIF1-γ autoantigens, which are reportedly expressed strongly in mammalian embryos, might have contributed to the onset of PM/DM ( 28 - 30 ). We also found another three cases of DM that developed in the postpartum period and were MSA-positive ( 31 - 33 ). Among them, anti-Jo-I, anti-SRP, and anti-Mi-2 antibody were detected in one case each.…”

Section: Discussionmentioning

confidence: 54%

Clinical and Serological Features and Pregnancy Outcomes in Women with Polymyositis/Dermatomyositis: A Case-based Review

et al. 2022

View full text Add to dashboard Cite

We encountered a 30-year-old woman who developed dermatomyositis during pregnancy and was positive for anti-Mi-2 antibodies. She was successfully treated with prednisolone and tacrolimus and delivered a healthy child. We reviewed the cases of idiopathic inflammatory myositis (IIM) that developed during pregnancy that were published after the year 2000 to elucidate the profile of myositis-specific antibodies (MSAs) in them and to evaluate their obstetric outcomes. In cases with IIM that developed during pregnancy, anti-Mi-2, anti-TIF1-g, anti-Jo-1, and anti-EJ antibodies was detected in one case each. The obstetric outcomes of the IIM-complicated pregnancies were poor, especially when complicated with active maternal myositis. Further studies focusing on the possible causal relationships between MSAs and cases with IIM that developed during pregnancy are needed. For better obstetric outcomes, appropriate suppression of the maternal disease activity using immunosuppressants and vigilance regarding the patient's requirement of Caesarean section is important.

show abstract

Section: Discussionmentioning

confidence: 54%

Clinical and Serological Features and Pregnancy Outcomes in Women with Polymyositis/Dermatomyositis: A Case-based Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There have been only a few reported cases of IMNM during pregnancy. Previously reported cases of IMNM associated with pregnancy are summarized in Table 1 4–10 . Four cases, including the present case, developed and were diagnosed during pregnancy, and three cases developed postpartum.…”

Section: Discussionmentioning

confidence: 79%

“…Previously reported cases of IMNM associated with pregnancy are summarized in Table 1. [4][5][6][7][8][9][10] Four cases, including the present case, developed and were diagnosed during pregnancy, and three cases developed postpartum. In all three cases of recurrence, treatment was interrupted at the time of pregnancy, suggesting that recurrence due to the interruption of treatment may be more important than exacerbation of symptoms due to pregnancy.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of seronegative immune‐mediated necrotizing myopathy developing during pregnancy: A case report and literature review

Hayashi,

Ozono,

Beck

et al. 2023

Neurology & Clinical Neurosc

View full text Add to dashboard Cite

Immune‐mediated necrotizing myopathy (IMNM) is an idiopathic inflammatory myopathy characterized by limb weakness, markedly elevated serum creatine kinase (CK), and muscle fiber necrosis without lymphocytic infiltration. Here, we present a case of IMNM that developed during pregnancy. The patient was treated immediately with systemic corticosteroids, and muscle weakness and serum CK levels were improved without adverse effects on the pregnancy. As there are only a few reports of IMNM during pregnancy, the clinical course and treatment of IMNM during pregnancy are discussed with a review of the literature.

show abstract

“…Regarding the disease activity of preexisting DM/PM during pregnancy, DM/PM remained inactive/in remission during pregnancy in 105 cases where 50 were in the active phase. Increased activity (flare/exacerbation/relapse) of DM/PM was observed during pregnancy in six patients 9–12 and after delivery in nine patients 5,14–16 . Decreased disease activity (disease improvement/resolution) during gestation and the postpartum period was documented in eight 5,17 and three 14 cases, respectively.…”

Section: Resultsmentioning

confidence: 95%

“…Increased activity (flare/exacerbation/relapse) of DM/PM was observed during pregnancy in six patients [9][10][11][12] and after delivery in nine patients. 5,[14][15][16] Decreased disease activity (disease improvement/resolution) during gestation and the postpartum period was documented in eight 5,17 and three 14 cases, respectively.…”

Section: Pregnancy In Dm/pmmentioning

confidence: 99%

Pregnancy in adult‐onset dermatomyositis/polymyositis: A systematic review

Tang

Zhou

Lan

et al. 2022

American J Rep Immunol

View full text Add to dashboard Cite

Background: Idiopathic inflammatory myopathy (IIM) in pregnancy is uncommon but may result in complications for both mother and the fetus. Aim:In this systematic review, we summarized the current literature investigating outcomes of pregnancy related to the dermatomyositis/polymyositis (DM/PM) process. Content:We searched PubMed, Embase, Cochrane Library, and Web of Science databases and included 61 studies reporting the disease course, pregnancy outcomes, and management of both pregnancy and DM/PM in the final analysis.The specific information of 221 pregnancies was extracted and these pregnancies were divided into three distinct forms: pregnancies after disease onset (n = 159), pregnancies with new disease onset (n = 37), and pregnancies followed by postpartum onset (n = 25). In most cases, DM/PM disease activity remained stable or improved throughout pregnancy (80.2%) and the postpartum period (83.9%). Active DM/PM during pregnancy significantly increased the risk of stillbirth or neonatal death (12% vs. 1%, P = .005) and preterm birth (34.7% vs. 11%, P < .001). The rates of other poor outcomes (total fetal loss, low birth weight, and intrauterine growth retardation) were also increased in pregnancies with active disease. Mainstay treatments for active DM/PM during pregnancy are glucocorticoids and intravenous immunoglobins. Implications:The present results underline the importance of good control of myopathy in optimizing the pregnancy outcomes of women with DM/PM.

show abstract

Polymyositis anti-SRP antibodies and pregnancy about 2 cases

Cited by 6 publications

References 10 publications

Clinical and Serological Features and Pregnancy Outcomes in Women with Polymyositis/Dermatomyositis: A Case-based Review

Clinical and Serological Features and Pregnancy Outcomes in Women with Polymyositis/Dermatomyositis: A Case-based Review

Successful treatment of seronegative immune‐mediated necrotizing myopathy developing during pregnancy: A case report and literature review

Pregnancy in adult‐onset dermatomyositis/polymyositis: A systematic review

Contact Info

Product

Resources

About